Exploring our Financial Future
Here at OsNovum, we need to deal with facts. When treating a patient, you must put aside any bias or dogma and honestly critique how your patient responds to therapy. You cannot let what you want to happen cloud the reality of what is actually happening. This is ingrained in us and as a result we cannot look at business any differently.
For this reason, you will not find a detailed business plan or income projections on the Wefunder fundraising website. I am sorry but when we look at business plans or income projections, we don’t see them as facts. To us, they seem more like fiction and we just can’t go there. However, as many of you have already invested in OsNovum, I can give you some facts that will give you an idea of OsNovum’s income potential over the coming years.
Let’s use the most conservative estimate possible and let’s limit the patient pool to just the United States.
50% of all women in the U.S. over the age of 50 will have an osteoporotic fracture in their lifetime. There are 60 million women in the U.S. over 50. So that leaves 30 million with at least one fracture. These 30 million will be those whose medications have failed and will be directed to seek our care. With that in mind, let’s say we treat just 10% of those 30 million by year 5. With 3 million patients at $5,000 each, this equates to $15,000,000,000. That’s $15 billion.
This assessment does not include:
- Women who get treated prior to a fracture
- Men who also suffer from osteoporosis
- Patients who get more than one bone treated
- Patients under 50 who are already suffering from osteoporosis or low bone density
Additionally, OsNovum is planned to treat not only osteoporosis, but the frailty of aging, which will be something that virtually everyone will want. For osteoporosis, OsNovum is a single injection, with no downtime, less pain than a dental filling, and no side effects. When the pharmaceutical industry sees their lucrative osteoporosis market challenged, we could easily be bought out long before year 5. I don’t like making these projections not because they are not accurate, but because they seem fanciful.
Americans are already spending a significant amount of money on pharmaceuticals that yield systemic side effects and minimal net benefits. With OsNovum, patients will spend a fraction of that cost toward something that produces fast, safe, and effective results using a minimally invasive process.
When patients become aware of OsNovum, we believe we will become the front line choice for treating weakened bones.